CN111187856A - Cpf1 kit for rapid detection of new coronavirus nucleic acid and preparation method and application thereof - Google Patents
Cpf1 kit for rapid detection of new coronavirus nucleic acid and preparation method and application thereof Download PDFInfo
- Publication number
- CN111187856A CN111187856A CN202010091557.6A CN202010091557A CN111187856A CN 111187856 A CN111187856 A CN 111187856A CN 202010091557 A CN202010091557 A CN 202010091557A CN 111187856 A CN111187856 A CN 111187856A
- Authority
- CN
- China
- Prior art keywords
- cpf1
- nucleic acid
- cov
- sars
- detection
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000001514 detection method Methods 0.000 title claims abstract description 96
- 150000007523 nucleic acids Chemical class 0.000 title claims abstract description 82
- 102000039446 nucleic acids Human genes 0.000 title claims abstract description 76
- 108020004707 nucleic acids Proteins 0.000 title claims abstract description 76
- 241000711573 Coronaviridae Species 0.000 title claims abstract description 16
- 238000002360 preparation method Methods 0.000 title claims description 17
- 238000001216 nucleic acid method Methods 0.000 title description 3
- 241001678559 COVID-19 virus Species 0.000 claims abstract description 83
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 59
- 108020004414 DNA Proteins 0.000 claims description 54
- 102000053602 DNA Human genes 0.000 claims description 54
- 101100329224 Coprinopsis cinerea (strain Okayama-7 / 130 / ATCC MYA-4618 / FGSC 9003) cpf1 gene Proteins 0.000 claims description 25
- 101150059443 cas12a gene Proteins 0.000 claims description 25
- 238000001917 fluorescence detection Methods 0.000 claims description 20
- 102000004169 proteins and genes Human genes 0.000 claims description 19
- 238000000034 method Methods 0.000 claims description 15
- 101150013191 E gene Proteins 0.000 claims description 14
- 238000011901 isothermal amplification Methods 0.000 claims description 11
- 239000012634 fragment Substances 0.000 claims description 8
- 230000000007 visual effect Effects 0.000 claims description 8
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 7
- 238000013518 transcription Methods 0.000 claims description 7
- 230000035897 transcription Effects 0.000 claims description 7
- 101100038645 Streptomyces griseus rppA gene Proteins 0.000 claims description 6
- 230000008685 targeting Effects 0.000 claims description 6
- 102000004190 Enzymes Human genes 0.000 claims description 5
- 108090000790 Enzymes Proteins 0.000 claims description 5
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 5
- 238000013461 design Methods 0.000 claims description 5
- 238000000338 in vitro Methods 0.000 claims description 5
- 238000000746 purification Methods 0.000 claims description 5
- 108020004705 Codon Proteins 0.000 claims description 4
- 238000001261 affinity purification Methods 0.000 claims description 4
- 239000003153 chemical reaction reagent Substances 0.000 claims description 4
- 239000013604 expression vector Substances 0.000 claims description 4
- 238000002372 labelling Methods 0.000 claims description 4
- 239000002808 molecular sieve Substances 0.000 claims description 4
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 claims description 4
- 230000002194 synthesizing effect Effects 0.000 claims description 4
- BZTDTCNHAFUJOG-UHFFFAOYSA-N 6-carboxyfluorescein Chemical compound C12=CC=C(O)C=C2OC2=CC(O)=CC=C2C11OC(=O)C2=CC=C(C(=O)O)C=C21 BZTDTCNHAFUJOG-UHFFFAOYSA-N 0.000 claims description 3
- 101800005109 Triakontatetraneuropeptide Proteins 0.000 claims description 3
- 230000006698 induction Effects 0.000 claims description 3
- 238000005457 optimization Methods 0.000 claims description 3
- 238000010839 reverse transcription Methods 0.000 claims description 3
- NMEHNETUFHBYEG-IHKSMFQHSA-N tttn Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 NMEHNETUFHBYEG-IHKSMFQHSA-N 0.000 claims description 3
- 239000013598 vector Substances 0.000 claims description 3
- 238000002795 fluorescence method Methods 0.000 abstract description 12
- 230000035945 sensitivity Effects 0.000 abstract description 9
- 238000003745 diagnosis Methods 0.000 abstract description 6
- 230000008901 benefit Effects 0.000 abstract description 4
- 230000004907 flux Effects 0.000 abstract description 2
- 108091079001 CRISPR RNA Proteins 0.000 description 34
- 239000000523 sample Substances 0.000 description 22
- 238000006243 chemical reaction Methods 0.000 description 21
- 108020004682 Single-Stranded DNA Proteins 0.000 description 17
- 241000700605 Viruses Species 0.000 description 12
- 239000000047 product Substances 0.000 description 8
- 230000000694 effects Effects 0.000 description 7
- 230000003612 virological effect Effects 0.000 description 7
- 239000013614 RNA sample Substances 0.000 description 6
- 108091033409 CRISPR Proteins 0.000 description 5
- 241000315672 SARS coronavirus Species 0.000 description 5
- 230000003321 amplification Effects 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- 238000003199 nucleic acid amplification method Methods 0.000 description 5
- 239000003161 ribonuclease inhibitor Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 238000010354 CRISPR gene editing Methods 0.000 description 4
- 102100035102 E3 ubiquitin-protein ligase MYCBP2 Human genes 0.000 description 4
- 201000003176 Severe Acute Respiratory Syndrome Diseases 0.000 description 4
- 238000003776 cleavage reaction Methods 0.000 description 4
- 238000003757 reverse transcription PCR Methods 0.000 description 4
- 238000012163 sequencing technique Methods 0.000 description 4
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 4
- 208000025721 COVID-19 Diseases 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 101000674278 Homo sapiens Serine-tRNA ligase, cytoplasmic Proteins 0.000 description 3
- 101000674040 Homo sapiens Serine-tRNA ligase, mitochondrial Proteins 0.000 description 3
- 102100040516 Serine-tRNA ligase, cytoplasmic Human genes 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 239000007795 chemical reaction product Substances 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 108010042407 Endonucleases Proteins 0.000 description 2
- 102000004533 Endonucleases Human genes 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 206010035664 Pneumonia Diseases 0.000 description 2
- 206010036790 Productive cough Diseases 0.000 description 2
- 208000037847 SARS-CoV-2-infection Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 230000005284 excitation Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- 210000002345 respiratory system Anatomy 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 238000004088 simulation Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 210000003802 sputum Anatomy 0.000 description 2
- 208000024794 sputum Diseases 0.000 description 2
- 229940113082 thymine Drugs 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 238000010446 CRISPR interference Methods 0.000 description 1
- 238000010443 CRISPR/Cpf1 gene editing Methods 0.000 description 1
- 230000007018 DNA scission Effects 0.000 description 1
- 108010008532 Deoxyribonuclease I Proteins 0.000 description 1
- 102000007260 Deoxyribonuclease I Human genes 0.000 description 1
- 108010053770 Deoxyribonucleases Proteins 0.000 description 1
- 102000016911 Deoxyribonucleases Human genes 0.000 description 1
- 108020005004 Guide RNA Proteins 0.000 description 1
- 206010025080 Lung consolidation Diseases 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 208000002151 Pleural effusion Diseases 0.000 description 1
- 230000006819 RNA synthesis Effects 0.000 description 1
- 102000018120 Recombinases Human genes 0.000 description 1
- 108010091086 Recombinases Proteins 0.000 description 1
- 241000295644 Staphylococcaceae Species 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 108020000999 Viral RNA Proteins 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 210000005006 adaptive immune system Anatomy 0.000 description 1
- 238000012197 amplification kit Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 238000003766 bioinformatics method Methods 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000013170 computed tomography imaging Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 239000012470 diluted sample Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000012154 double-distilled water Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000012869 ethanol precipitation Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 238000011008 operational qualification Methods 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000001124 posttranscriptional effect Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 239000011535 reaction buffer Substances 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000011896 sensitive detection Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 238000011179 visual inspection Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
- C12Q1/701—Specific hybridization probes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
The invention discloses a Cpf1 fluorescent kit for rapidly detecting new coronavirus SARS-CoV-2 nucleic acid, which comprises a Cpf1 detection system and a fluorescent reporter system suitable for rapidly detecting SARS-CoV-2. In the invention, a series of specific crRNAs are designed aiming at 4 genes of orf1a, orf1b, N and E of SARS-CoV-2 virus, and SARS-CoV-2 virus nucleic acid can be sensitively and specifically detected. The invention adopts Cpf1 to detect the new coronavirus SARS-CoV-2 for the first time, and has the advantages of high sensitivity, strong specificity, short time consumption, high flux, direct interpretation by naked eyes, no dependence on large-scale experimental equipment and the like. These advantages make the Cpf1 fluorescence method developed by the invention convenient for clinical one-line rapid detection and identification diagnosis of the SARS-CoV-2 nucleic acid of the new coronavirus.
Description
Technical Field
The invention relates to a rapid detection method and a kit for a new coronavirus nucleic acid, in particular to a rapid diagnosis method and a kit for a new coronavirus SARS-CoV-2 virus nucleic acid based on Cpf1 fluorescence detection, belonging to the field of biotechnology.
Background
The international committee for viral classification (ICTV) formally classified the new coronavirus (2019-nCoV) as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The World Health Organization (WHO) announces that the disease caused by this virus is under the positive name COVID-19.
At present, the diagnosis of the new coronary pneumonia mainly comprises two types of virus nucleic acid molecule detection and chest imaging detection. The chest imaging detection mainly depends on the CT imaging result of the chest and lung part for judgment: the early stage shows multiple small spot shadows and interstitial changes, and the lung-external zone is obvious, so that the two lungs develop multiple wear glass shadows and infiltrative shadows. In severe cases, lung consolidation changes, even 'white lung' and pleural effusion are rare. However, the chest-lung CT examination is required to be specialized. In the approach of molecular biology, there are two approaches commonly used at present: gene sequencing and nucleic acid detection of the virus. The second generation sequencing can detect trace substances, but most hospitals do not have the assistance of sequencing equipment and a biological information team, and the detection period is high in cost and long, so that the second generation sequencing is not suitable for screening.
Current diagnostic methods rely on viral nucleic acid detection: identified by real-time reverse transcription polymerase chain reaction (rRT-PCR). Samples of the upper and lower respiratory tract, such as bronchial or alveolar lavage fluid and profuse sputum, were collected for each case, along with serum collected at the beginning of onset and 14 days after onset. At present, on the basis of meeting the standard of suspected cases, rRT-PCR detection is carried out on samples such as sputum, throat swabs, lower respiratory tract secretion and the like, and SARS-CoV-2 nucleic acid is positive, so that SARS-CoV-2 infection can be diagnosed. The detection of viral nucleic acids by rRT-PCR is mainly subject to: the quality of the kit and the number of P3 laboratories capable of undertaking clinical tests, the accuracy and stability of the P3 laboratory equipment, the number of workers capable of skilled stable operation, the need for expensive laboratory equipment, and the long test time.
At present, no effective treatment means or vaccine aiming at SARS-CoV-2 infection exists, and disease control mainly depends on strict physical isolation to cut off the transmission path, thereby directly causing serious economic loss. In view of the broad and rapid transmission pathway of SARS-CoV-2, rapid diagnosis of the virus is urgently required, which is very important for prevention and diagnosis of the disease. The SARS-CoV-2 is detected accurately and quickly, so that the quarantine decision can be taken immediately and immediately, and the purpose of blocking the diffusion risk is achieved.
CRISPR-Cas (Clustered differentiated short palindromic repeats, CRISPRs) is an adaptive immune system in bacteria, and Cas proteins degrade foreign nucleic acids through RNA-guided nuclease targeting [1,2 ]. Among them, CRISPR-Cas12a (Cpf1) belongs to Cas enzyme second family, and is used to guide RNA to guide double-stranded DNA cleavage of single RuvC catalytic domain. The Cpf1 enzymes recognize a Thymine (Thymine, T) nucleotide rich spacer adjacent motif (PAM) 3, catalyze their own guided CRISPR RNA (crRNA) maturation 4, and specifically recognize and cleave complementary paired double-stranded dna (dsdna) 3. Strong non-specific single-stranded DNA (ssdna) trans-cleavage activity can be induced when the CRISPR/Cpf1 protein recognizes cleavage of the target double-stranded DNA in a sequence-specific manner [5 ]. Based on the above properties of Cpf1, we developed a rapid and accurate assay for detecting SARS-CoV-2 viral nucleic acid in clinical specimens. Firstly, the clinical sample is processed by virus inactivation treatment to release SARS-CoV-2 nucleic acid in the sample to be detected. Viral RNA is Reverse Transcribed (RT) to obtain DNA and Recombinase Polymerase Amplification (RPA) is performed [6 ]. The Cpf1-crRNA complex binds to and cleaves the target dsDNA, which activates the trans-cleavage of ssDNA. Fluorescent reporter molecules coupled to ssDNA generate a fluorescent signal upon cleavage. The novel method called DNA endonuclease targeting CRISPR trans-reporter gene provides a powerful platform for rapidly and accurately detecting the novel coronavirus.
Reference to the literature
1.R,B.,et al.,CRISPR provides acquired resistance against viruses inprokaryotes. Science(New York,N.Y.),2007.315(5819):p.1709-12.
2.LA,M.and S.EJ,CRISPR interference limits horizontal gene transferin staphylococci by targeting DNA.Science(New York,N.Y.),2008.322(5909):p.1843-5.
3.B,Z.,et al.,Cpf1 is a single RNA-guided endonuclease of a class2CRISPR-Cas system.Cell,2015.163(3):p.759-71.
4.I,F.,et al.,The CRISPR-associated DNA-cleaving enzyme Cpf1 alsoprocesses precursor CRISPR RNA.Nature,2016.532(7600):p.517-21.
5.JS,C.,et al.,CRISPR-Cas12a target binding unleashes indiscriminatesingle-stranded DNase activity.Science(New York,N.Y.),2018.360(6387):p. 436-439.
6.O,P.,et al.,DNA detection using recombination proteins.PLoSbiology,2006. 4(7):p.e204.
Disclosure of Invention
The invention aims to solve the problem of rapid detection of the clinical new coronavirus SARS-CoV-2, and provides a rapid visualized Cpf1 kit for rapid detection of the new coronavirus SARS-CoV-2 nucleic acid with high sensitivity and strong specificity and a detection method thereof.
In order to achieve the above object, the present invention provides a Cpf1 kit for rapid nucleic acid detection of novel coronavirus SARS-CoV-2, comprising a fluorescent detection system of Cpf1 suitable for rapid nucleic acid detection of novel coronavirus SARS-CoV-2; the Cpf1 fluorescence detection system comprises: a specific crRNA, Cpf1 protein and single stranded DNA (ssDNA) reporter system for the detection segments of the novel coronavirus SARS-CoV-2 genes orf1a, orf1b, N and E;
the specific crRNA is: any one or more of orf1a-crRNA1 to orf1a-crRNA2 for orf1a gene, orf1b-crRNA1 to orf1b-crRNA3 for orf1b gene, N-crRNA1 to N-crRNA2 for N gene and E-crRNA1 to E-crRNA2 for E gene, the sequences of which are SEQ No.1 to SEQ No. 9; the single-stranded DNA (ssDNA) report system comprises ssDNA FQreporters used for fluorescence detection of a microplate reader or direct visual interpretation under a fluorescent lamp; the ssDNA FQ reporter is ssDNA labeled by 6-carboxyfluorescein (6-FAM) and a fluorescence quencher (BHQ1), and the labeling products are as follows: the gene is/56 FAM/TTTATTT/3BHQ1/, named ssDNA FQ reporter/56 FAM/TTTATTT/3BHQ 1/.
Preferably, the specific crRNA is: orf1a-crRNA1 and orf1a-crRNA2 mixed in equal proportion are named orf1 a-crRNAmix; or orf1b-crRNA1, orf1b-crRNA2 and orf1b-crRNA3 which are mixed in equal proportion and are named orf1 b-crRNAmix; or N-crRNA1 and N-crRNA2 which are mixed in equal proportion and are named as N-crRNAmix; or E-crRNA1 and E-crRNA2 which are mixed in equal proportion and are named as E-crRNAmix.
The invention also provides a preparation method of the Cpf1 reagent kit for rapidly detecting the SARS-CoV-2 nucleic acid of the novel coronavirus, which is characterized in that the preparation method of the specific crRNA comprises the following steps: aiming at SARS-CoV-2 virus nucleic acid orf1a, orf1b, N and E genes with the sequences from SEQ NO.10 to SEQ NO.13, searching a targeting sequence containing cpf1 recognition sequence (PAM) TTTN, and designing crRNA with the length of 23 bp; after the design is finished, preparing crRNA;
the preparation method of the Cpf1 protein comprises the following steps: optimizing prokaryotic codon aiming at cpf1 protein nucleic acid sequence to obtain sequence SEQ NO.14, constructing pET28a expression vector, performing low-temperature induced soluble protein expression, and obtaining target protein through affinity purification and molecular sieve purification;
the preparation method of the Cpf1 protein comprises the following steps: prokaryotic codon optimization is carried out on cpf1 protein nucleic acid sequence to obtain sequence SEQ NO.14, pET28a expression vector is constructed, low-temperature induction soluble protein expression is carried out, and target protein is obtained through affinity purification and molecular sieve purification.
Preferably, the preparation of the crRNA comprises constructing a vector pUC57-T7-crRNA, and obtaining the crRNA of interest by in vitro transcription; or directly synthesizing RNA corresponding to the crRNA sequence.
The Cpf1 kit for rapidly detecting the nucleic acid of the novel coronavirus SARS-CoV-2 can be used for fluorescence detection by a microplate reader and can also be used for fluorescence macroscopic detection. In the invention, when the fluorescence detection of a microplate reader is used, the detection exciting light is set to be 485-520 nm; when the direct detection is carried out by naked eyes, a light emitter capable of generating a 485nm wavelength light source is selected for detection.
When fluorescence detection is used, SARS-CoV-2 viral nucleic acid is present in the Cpf1 detection system and specifically activates the endonuclease activity of Cpf1 protein under the mediation of SARS-CoV-2 specific crRNA. After activation, the Cpf1 protein cleaves ssDNA FQ reporter labeled with a fluorescent group and a quenching group, so that the activated fluorescent group is released, and a fluorescence reading or a green reaction visible to the naked eye can be detected by using a microplate reader. Correspondingly, when SARS-CoV-2 virus nucleic acid does not exist in the sample to be detected, no fluorescence reading or no visible green reaction can be obtained.
The invention also provides a method for quickly detecting the nucleic acid of the novel coronavirus SARS-CoV-2, which is characterized by adopting the Cpf1 kit for quickly detecting the nucleic acid of the novel coronavirus SARS-CoV-2.
Preferably, the method for rapidly detecting the nucleic acid of the novel coronavirus SARS-CoV-2 comprises the following steps:
step a: inactivating viruses of the sample by utilizing a nucleic acid quick release reagent and releasing nucleic acid in the sample to be detected;
step b: amplifying nucleic acid in a sample to be detected by using an isothermal amplification primer: b, adding the products obtained in the step a into an RT-RPA isothermal amplification system by using specific primers SEQ NO.15 to SEQ NO.22 of SARS-CoV-2 virus nucleic acid orf1a, orf1b, N and E gene fragments, and reacting for 25min at 37 ℃ to obtain specific products;
step c: when the Cpf1 detection system is used for identifying and cutting SARS-CoV-2 virus nucleic acid orf1a, orf1b, N and E gene fragments: adding the product obtained in the step b into a Cpf1 detection system, and reacting for 25min at 37 ℃;
step d: directly detecting and interpreting whether SARS-CoV-2 virus nucleic acid exists in the sample to be detected by utilizing a fluorescent microplate reader or a fluorescent lamp.
Compared with the prior art, the invention has the beneficial effects that:
(1) the invention realizes the high sensitivity, high specificity and rapid visual detection of SARS-CoV-2 nucleic acid by using Cpf1 specific recognition nucleic acid fluorescence detection technology. Genetic bioinformatics analysis, SARS-CoV-2 virus sequence and SARS and bat-related SARS virus sequence in NCBI database are designed to aim at orf1a, orf1b, N and E gene fragment differential crRNA. In order to ensure the detection specificity, the designed crRNA sequence is searched for genes comprising human, animal, plant and microorganism in the NCBI nucleic acid database, and the high homology matching is not determined. Based on the recognition of specific PAM sequence characteristics by Cpf1, 9 specific crRNAs were designed on orf1a, orf1b, N and E gene target sequences. Through detection, 9 crRNAs can specifically recognize 4 genes of SARS-CoV-2 virus orf1a, orf1b, N and E respectively. And aiming at the same sample to be detected, the method can simultaneously detect SARS-CoV-2 virus 4 genes orf1a, orf1b, N and E, and can effectively improve the detection accuracy and credibility.
(2) The invention relates to a Cpf1 new coronavirus SARS-CoV-2-based rapid species detection tool, which comprises a fluorescent lamp-based direct visual detection by naked eyes and can realize convenient and rapid result interpretation. The invention provides an accurate, rapid and simple detection method for the first line of basic level experiments and clinics.
(3) The invention discloses a series of Cpf1 reaction systems and crRNA combinations for detecting new coronavirus SARS-CoV-2 nucleic acid, and the sequences are shown in SEQ ID NO.1 to NO.9 in sequence. The invention adopts the Cpf1 fluorescence method to detect the new coronavirus SARS-CoV-2 for the first time, and has the advantages of high sensitivity, strong specificity, short time consumption, high flux, no dependence on large-scale experimental equipment and the like. These advantages make the Cpf1 fluorescence-based detection method developed by the invention conveniently used for the primary experiment and clinical one-line primary rapid detection and identification diagnosis of new coronary pneumonia.
Drawings
FIG. 1 is a schematic diagram of a method for rapid detection of the novel coronavirus SARS-CoV-2 nucleic acid based on Cpf 1;
FIG. 2 shows the fluorescence detection effect of different genes of new coronavirus detected by different crRNAs;
FIG. 3 shows the direct visual interpretation of different genes of different crRNAs of the new coronavirus;
FIG. 4 Cpf1 sensitivity for fluorescence detection of New coronavirus SARS-CoV-2;
FIG. 5 naked eye detection sensitivity of Cpf1 for detecting New coronavirus SARS-CoV-2;
FIG. 6 fluorescent detection of Cpf1 for rapid detection of the SARS-CoV-2 and SARS specificity of the novel coronavirus;
FIG. 7 direct visual inspection of Cpf1 to rapidly detect the specificity of the novel coronavirus SARS-CoV-2;
FIG. 8 simulation detection of clinical SARS-CoV-2 nucleic acid sample fluorescence detection results;
FIG. 9 simulation detection of clinical SARS-CoV-2 nucleic acid sample direct visual detection results;
Detailed Description
The invention will be further illustrated with reference to the following specific examples. It should be understood that these examples are for illustrative purposes only and are not intended to limit the scope of the present invention. Furthermore, it should be understood that various changes and modifications can be made by those skilled in the art after reading the teachings of the present invention, and such equivalents also fall within the scope of the appended claims.
In the invention: RPA amplification kitBasic kit was purchased from twist amp, inc; the crRNA in vitro Transcription cassette MEGAshortscript T7 Transcription Kit and the purification cassette MEGAclear Kit were purchased from Ambion; conventional reagents such as Tris-Base, NaCl, Tris-HCl, MgCl2, BSA and glycerol are available from ThermoFisher; the nucleic acid fragment for detection, the ssDNA probe and the RNA synthesis were completed by Nanjing Kinsley; the present invention uses a rapid nucleic acid release agent from nuozoken to obtain pre-treated nucleic acids.
The general technical schematic diagram of the invention is shown in the attached figure 1, and comprises the following 3 parts: preparation of nucleic acid samples to be detected, design and preparation of Cpf1 detection components, system construction and fluorescence detection.
Example 1: rapid and sensitive detection of SARS-CoV-2 gene fragment of new coronavirus
1.1 nucleic acid preparation
In this case, orf1a, orf1b, N and E gene fragments of the novel coronavirus SARS-CoV-2 are designed by referring to the sequence of NCBIWuhan-Hu-1 strain, synthesized by Nanjing Kingsler company and named pc-orf1a, pc-orf1b, pc-N and pc-E, and the corresponding sequences are SEQ NO.10 to SEQ NO.13, respectively.
RNA nucleic acid samples corresponding to orf1a, orf1b, N and E genes of the novel coronavirus SARS-CoV-2 were prepared by in vitro transcription. The specific operation is as follows: using MEGAShortscript T7 transcription kit (Thermo Fisher scientific), corresponding gene RNA samples, pcRNA-orf1a, pcRNA-orf1b, pcRNA-N and pcRNA-E, were transcribed using pc-orf1a, pc-orf1b, pc-N and pc-E as templates, respectively. The transcribed RNA was purified using MEGAclear kit (ThermoFisher Scientific) and recovered by ethanol precipitation; post-transcriptional RNA quality and concentration were determined and stored at-80 ℃ until use.
1.2 preparation of a CrRNA specific for SARS-CoV-2
Preparation of crRNA specific for SARS-CoV-2 the protocol was followed to search for a targeting sequence comprising the cpf1 recognition sequence (PAM) TTTN against orf1a, orf1b, N and E genes of SARS-CoV-2 and design a crRNA of 23bp length. Are designated orf1a-crRNA1 to orf1a-crRNA2 for orf1a gene, orf1b-crRNA1 to orf1b-crRNA3 for orf1b gene, N-crRNA1 to N-crRNA2 for N gene and E-crRNA1 to E-crRNA2 for E gene, respectively. After the design is complete, crRNA is prepared. The preparation of the crRNA can be carried out by synthesizing oligo by Nanjing Kinshire company, constructing vector pUC57-T7-crRNA, and obtaining the target crRNA through in vitro transcription, or can be carried out by directly synthesizing RNA corresponding to the crRNA sequence by Nanjing Kinshire company.
The crRNA of orf1a, orf1b, N and E genes of SARS-CoV-2 provided by the invention comprises SEQ NO.1 to SEQ NO.9, and the specific information is shown in Table 1:
TABLE 1 CrRNA specific for the nucleic acid of the novel coronavirus SARS-CoV-2
1.3 reverse transcription isothermal amplification reaction
In the present invention, reverse transcription isothermal amplification (RT-RPA) is used to pre-amplify single-stranded RNA (ssRNA) viral nucleic acids for the cpf1 detection reaction. RT-RPA amplification primers RT-RPA-F (forward primer) and RT-RPA-R (reverse primer) were designed and synthesized according to isothermal amplification reaction requirements, corresponding to SEQ No.15 to SEQ No.22 (Table 2). And (3) obtaining a sample to be detected by amplification by referring to the RT-RPA isothermal amplification operation step. The specific operation is as follows: isothermal amplification was performed in a 50. mu.L reaction system. mu.L of RNA sample, (18.5-x) mu.L of ddH2O, 2. mu.L of RT-RPA-F, 2. mu.L of RT-RPA-R and 25. mu.L of reaction buffer solution are mixed evenly, added into a reaction tube and dissolved evenly. Finally, 2.5. mu.L of ethyl acetate was addedMagnesium, mixed and incubated at 39 ℃ for 25 minutes. And (4) carrying out next detection on the RT-RPA product.
TABLE 2 nucleic acid specific RT-RPA primer sequences for novel coronavirus nCoV
1.4 in this case, the 20 μ L system is used for the detection of the new coronavirus cpf1 as shown in table 3, but the method is not limited to the following steps:
TABLE 3 detection System for New coronavirus cpf1
1.5 full-wavelength ELIASA fluorescence detection
In the fluorescence detection of the microplate reader, 2 mu L of Buffer, 1 mu L of RnaseInhibitors, 1 mu L of Cpf1, 1 mu L of ssDNA FQ reporter, 5 mu L of RPA sample, 1 mu L of crRNA and 9 mu L H2O are sequentially added into the Cpf1 to the target gene detection system. The components are mixed evenly and then react for 25min at 37 ℃. Wherein, the concentration of RNase Inhibitors in the reaction system is 40U/. mu.L, the concentration of Cpf1 is 200 ng/. mu.L, the concentration of ssDNA FQ reporter is 25 pM/. mu.L, and the concentration of crRNA is 1 nM/. mu.L.
First, the detection efficiency of crRNA against SARS-CoV-2 virus nucleic acid was sequentially examined. And (3) adding 1 mu L of crRNA into a Cpf1 detection system respectively, keeping other components consistent, mixing uniformly, reacting at 37 ℃ for 25min, and carrying out subsequent result detection and judgment on the reaction products.
The Cpf1 detection system was assessed for activity using fluorescence detection. And (3) measuring the fluorescence of the detection reaction by using a full-wavelength microplate reader, wherein the excitation wavelength is 485nm, the emission wavelength is 520nm, and the fluorescence value of 25min of reading and detection is taken as the reaction value. The results of the reaction detection for the new coronavirus SARS-CoV-2 are shown in FIG. 2. The result shows that in the detection system, crRNA aiming at different gene segments can efficiently and specifically detect corresponding orf1a, orf1b, N and E gene segments.
1.5 direct interpretation by naked eye with fluorescent display
Meanwhile, products obtained after the cpf1 detection reaction is carried out for 25min are placed under a 485nm laser lamp, and the results can be directly interpreted by naked eyes. When the crRNA specifically recognizes the target nucleic acid fragment, the color of the reaction product changes from colorless to fluorescent green; correspondingly, if no corresponding target nucleic acid is to be detected, the color of the reaction product remains uncolored. After 25min of reaction detection at cpf1, visual interpretation was performed under fluorescent light and recorded by photography. As shown in FIG. 3, crRNAs aiming at different gene segments can efficiently and specifically detect corresponding orf1a, orf1b, N and E gene segments.
In view of the consistent detection effect of the crRNA for orf1a, orf1b, N and E genes in the present embodiment, orf1a-crRNA1 to orf1a-crRNA2 for orf1a gene were mixed in equal proportion to obtain orf1 a-crRNAmix; mixing orf1b-crRNA1 to orf1b-crRNA3 aiming at orf1b gene in equal proportion to obtain orf1 b-crRNAmix; mixing N-crRNA1 to N-crRNA2 in equal proportion aiming at the N gene to obtain N-crRNAmix; E-crRNA1 to E-crRNA2 aiming at the E gene are mixed in equal proportion to obtain E-crRNAmix. In the subsequent detection, orf1a-crRNAmix detects orf1a gene, orf1b-crRNAmix detects orf1b gene, N-crRNAmix detects N gene and E-crRNAmix detects E gene.
Example 2: high-sensitivity SARS-CoV-2 nucleic acid detection based on cpf1 fluorescence method
In this case, the following detection was performed to determine the sensitivity of cpf1 fluorescence method for SARS-CoV-2 detection.
First, the molecular weight of the test fragment was calculated from RNA samples pcRNA-orf1a, pcRNA-orf1b, pcRNA-N and pcRNA-E corresponding to orf1a, orf1b, N and E gene fragments of SARS-CoV-2, and subjected to 10-fold gradient dilution to obtain test samples containing 2 × E7, 2 × E6, 2 × E5, 2 × E4, 2 × E3, 2 × E2, 2 × E1 and 2 × E0 copies (copy/μl) per microliter.
The cpf 1-specific reaction was carried out on the diluted sample by the fluorescence method, and detection and interpretation of the fluorescence result were carried out in accordance with the detection procedure in example 1. The operation is briefly described as follows: the sample is diluted in 2. mu.L gradient and added into a 50. mu.L RT-RPA isothermal amplification reaction system for amplification. And (3) adding 10 mu L of isothermal amplification product into a 20 mu L cpf1 fluorescent nucleic acid detection system, uniformly mixing, and reacting at 37 ℃ for 25min to judge the fluorescence result.
In this case, cpf1 fluorescence method is used to detect the new coronavirus SARS-CoV-2, and enzyme-labeling instrument is used to detect (FIG. 4), so that high sensitivity detection of 4e0 copy virus can be realized; high sensitivity detection of 4e1 copies of virus was achieved using fluorescent visual detection (FIG. 5).
Example 3: high specificity detection of SARS-CoV-2 nucleic acid based on cpf1 fluorescence method
In this example, the following tests were carried out to determine whether the fluorescence method cpf1 could perform a highly specific reaction on SARS-CoV-2 and could effectively distinguish SARS virus from SARS-CoV-2 virus.
First, according to the present invention, for SARS-CoV-2 virus nucleic acid detection segments pcRNA-orf1a, pcRNA-orf1b, pcRNA-N and pcRNA-E, RNA samples of SARS virus-corresponding gene sequences were prepared as described in example 1: ncRNA-orf1a, ncRNA-orf1b, ncRNA-N and ncRNA-E.
Next, referring to example 1, SARS-CoV-2 and SARS-detected sample were prepared by RT-RPA reaction and amplified separately.
In the fluorescence detection, 2. mu.L of Buffer, 1. mu.L of LRnase Inhibitors, 1. mu.L of Cpf1, 1. mu.L of ssDNA FQ reporter, 1. mu.L of crRNA and 10. mu.L of detection sample are sequentially added into the Cpf1 detection system. The components are mixed evenly and reacted for 25min at 37 ℃. In the detection system, the concentration of RNase Inhibitors is 40U/. mu.L, the concentration of Cpf1 is 200 ng/. mu.L, the concentration of ssDNADB reporter is 25 pM/. mu.L, and the concentration of crRNA is 1 nM/. mu.L.
In this example, the detection activity of the Cpf1 detection system was determined using fluorescence detection. And (3) measuring the fluorescence of the detection reaction by using a full-wavelength enzyme labeling instrument, wherein the excitation wavelength is 485nm, the emission wavelength is 520nm, and the fluorescence value at the time of detection for 25min is taken as the reaction value. As shown in FIG. 6, the cpf1 fluorescence method of the present invention can detect SARS-CoV-2 virus nucleic acid with high specificity and has no response to SARS virus.
In the embodiment, after the cpf1 detection system reacts for 25min, the fluorescence reaction of the detection product can be interpreted by naked eyes under a 485nm laser lamp. As shown in FIG. 7, the cpf1 fluorescence method of the present invention can detect SARS-CoV-2 virus nucleic acid with high specificity and has no response to SARS virus.
Example 4: rapid detection of clinical SARS-CoV-2 virus nucleic acid by simulating cpf1 fluorescence method
The present embodiment simulates the nucleic acid of clinical tissue sample for fast detection of SARS-CoV-2, and the detection does not involve any clinical new coronavirus sample, and all the operational qualification is performed according to relevant laws and regulations and relevant regulations.
In this case, first, SARS-CoV-2 virus nucleic acid-corresponding RNA samples (pcRNA-orf1a, pcRNA-orf1b and pcRNA-N) and SARS virus nucleic acid-corresponding RNA samples (pcRNA-E ncRNA-orf1a, ncRNA-orf1b, ncRNA-N and ncRNA-E) in example 3 were spotted onto a pharyngeal swab to simulate clinical samples and tested.
First, virus inactivation and viral nucleic acid release are performed. This example uses a rapid nucleic acid release agent from Novomedium to obtain pre-treated nucleic acids. The method comprises the following steps: throat swabs were added to 50 μ L PBS to simulate lysis of virus into the liquid. And adding 20 mul of nucleic acid lysate into 3 mul of sample to be detected, adding an RNase inhibitor, standing for 3 minutes at normal temperature, adding 20 mul of neutralizing solution, and uniformly mixing for next detection. In the Cpf1 assay, 5. mu.L of each sample to be assayed was subjected to RT-RPA pre-amplification in the same manner as in example 1 to obtain a Cpf1 assay sample.
In the Cpf1 detection system, 2. mu.L Buffer, 1. mu.L RNase Inhibitors, 1. mu.L Cpf1, 1. mu.L ssDNA FQ reporter, 10. mu.L RPA sample and 1. mu.L crRNA were sequentially added. The components are mixed evenly and reacted for 25min at 37 ℃.
In this embodiment, the detection result cpf1 can be directly determined by naked eyes under a microplate reader or a fluorescent lamp. As shown in FIG. 8, the cpf1 fluorescence method of the present invention can be effectively used for determining the clinical positive and negative samples by the detection of the microplate reader. Similarly, the simulated clinical positive and negative samples were visually determined efficiently under fluorescent light (FIG. 9).
SEQUENCE LISTING
<110> Shanghai science and technology university
<120> Cpf1 kit for rapid detection of new coronavirus nucleic acid, and preparation method and application thereof
<130>PCN1200195
<160>22
<170>PatentIn version 3.5
<210>1
<211>27
<212>DNA
<213>Artificial Sequence
<220>
<223>orf1a-crRNA1
<400>1
TTTGGTGGTGCATCGTGTTGTCTGTAC 27
<210>2
<211>27
<212>DNA
<213>Artificial Sequence
<220>
<223>orf1a-crRNA2
<400>2
TTTGTGACTTAAAAGGTAAGTATGTAC 27
<210>3
<211>27
<212>DNA
<213>Artificial Sequence
<220>
<223>orf1b-crRNA1
<400>3
TTTCACTCAATACTTGAGCACACTCAT 27
<210>4
<211>27
<212>DNA
<213>Artificial Sequence
<220>
<223>orf1b-crRNA2
<400>4
TTTTTAACATTTGTCAAGCTGTCA 27
<210>5
<211>27
<212>DNA
<213>Artificial Sequence
<220>
<223>orf1b-crRNA3
<400>5
TTTTAACATTTGTCAAGCTGTCACGGC 27
<210>6
<211>27
<212>DNA
<213>Artificial Sequence
<220>
<223>N-crRNA1
<400>
TTTCTTGAACTGTTGCGACTACGTGAT 27
<210>7
<211>27
<212>DNA
<213>Artificial Sequence
<220>
<223>N-crRNA2
<400>7
TTTGCTGCTGCTTGACAGATTGAACCA 27
<210>8
<211>27
<212>DNA
<213>Artificial Sequence
<220>
<223>E-crRNA1
<400>8
TTTCTTGCTTTCGTGGTATTCTTGCTA 27
<210>9
<211>27
<212>DNA
<213>Artificial Sequence
<220>
<223>E-crRNA2
<400>9
TTTCGTGGTATTCTTGCTAGTTACACT 27
<210>10
<211>299
<212>DNA
<213>Artificial Sequence
<220>
<223>pc-orf1a
<400>10
actggtactggtcaggcaataacagttacaccggaagccaatatggatcaagaatccttt 60
ggtggtgcatcgtgttgtctgtactgccgttgccacatagatcatccaaatcctaaagga 120
ttttgtgacttaaaaggtaagtatgtacaaatacctacaacttgtgctaatgaccctgtg 180
ggttttacacttaaaaacacagtctgtaccgtctgcggtatgtggaaaggttatggctgt 240
agttgtgatcaactccgcgaacccatgcttcagtcagctgatgcacaatcgtttttaa 299
<210>11
<211>299
<212>DNA
<213>Artificial Sequence
<220>
<223>pc-orf1b
<400>11
cacaccgtttctatagattagctaatgagtgtgctcaagtattgagtgaaatggtcatgt 60
gtggcggttcactatatgttaaaccaggtggaacctcatcaggagatgccacaactgctt 120
atgctaatagtgtttttaacatttgtcaagctgtcacggccaatgttaatgcacttttat 180
ctactgatggtaacaaaattgccgataagtatgtccgcaatttacaacacagactttatg 240
agtgtctctatagaaatagagatgttgacacagactttgtgaatgagttttacgcatat 299
<210>12
<211>228
<212>DNA
<213>Artificial Sequence
<220>
<223>pc-E
<400>12
atgtactcattcgtttcggaagagacaggtacgttaatagttaatagcgtacttcttttt 60
cttgctttcgtggtattcttgctagttacactagccatccttactgcgcttcgattgtgt 120
gcgtactgctgcaatattgttaacgtgagtcttgtaaaaccttctttttacgtttactct 180
cgtgttaaaaatctgaattcttctagagttcctgatcttctggtctaa 228
<210>13
<211>299
<212>DNA
<213>Artificial Sequence
<220>
<223>pc-N
<400>13
gctaacaatgctgcaatcgtgctacaacttcctcaaggaacaacattgccaaaaggcttc 60
tacgcagaagggagcagaggcggcagtcaagcctcttctcgttcctcatcacgtagtcgc 120
aacagttcaagaaattcaactccaggcagcagtaggggaacttctcctgctagaatggct 180
ggcaatggcggtgatgctgctcttgctttgctgctgcttgacagattgaaccagcttgag 240
agcaaaatgtctggtaaaggccaacaacaacaaggccaaactgtcactaagaaatctgc 299
<210>14
<211>3744
<212>DNA
<213>Artificial Sequence
<220>
<223> cpf1 protein nucleic acid sequence
<400>14
agcaagctgg aaaaatttac caactgctac agcctgagca agaccctgcg tttcaaagcg 60
atcccggttg gcaagaccca ggaaaacatt gacaacaaac gtctgctggt tgaggacgaa 120
aagcgtgcgg aggattataa aggtgtgaag aaactgctgg atcgttacta tctgagcttt 180
atcaacgacg tgctgcacag cattaagctg aaaaacctga acaactacat cagcctgttc 240
cgtaagaaaa cccgtaccga gaaggaaaac aaagagctgg aaaacctgga aatcaacctg 300
cgtaaggaga ttgcgaaggc gttcaagggt aacgagggct acaagagcct gttcaagaaa 360
gatatcatcg aaaccatcct gccggagttc ctggacgata aggacgaaat tgcgctggtt 420
aacagcttca acggttttac caccgcgttc accggcttct ttgataaccg tgagaacatg 480
tttagcgagg aagcgaaaag caccagcatc gcgttccgtt gcattaacga aaacctgacc 540
cgttacatca gcaacatgga cattttcgag aaggttgacg cgatctttga taaacacgag 600
gtgcaggaaa tcaaggagaa aattctgaac agcgactatg atgttgaaga tttctttgag 660
ggtgaattct ttaactttgt tctgacccaa gagggcatcg acgtgtacaa cgcgatcatt 720
ggtggcttcg tgaccgaaag cggcgagaag atcaaaggcc tgaacgagta cattaacctg 780
tataaccaga agaccaaaca aaagctgccg aaatttaagc cgctgtataa gcaggtgctg 840
agcgatcgtg aaagcctgag cttctacggc gagggctata ccagcgacga ggaagttctg 900
gaagtgtttc gtaacaccct gaacaaaaac agcgagatct tcagcagcat taagaaactg 960
gaaaagctgt tcaaaaactt tgacgagtac agcagcgcgg gtatctttgt taagaacggc 1020
ccggcgatca gcaccattag caaagatatc ttcggtgaat ggaacgtgat tcgtgacaag 1080
tggaacgcgg agtatgacga tatccacctg aagaaaaagg cggtggttac cgaaaagtac 1140
gaggacgatc gtcgtaaaag cttcaaaaag attggcagct ttagcctgga acagctgcaa 1200
gagtacgcgg acgcggatct gagcgtggtt gaaaaactga aggagatcat tatccagaag 1260
gttgatgaaa tctacaaagt gtatggtagc agcgagaagc tgttcgacgc ggattttgtt 1320
ctggagaaga gcctgaaaaa gaacgacgcg gtggttgcga tcatgaagga cctgctggat 1380
agcgtgaaaa gcttcgaaaa ctacattaag gcgttctttg gtgaaggcaa agagaccaac 1440
cgtgacgaga gcttctatgg cgattttgtt ctggcgtacg acatcctgct gaaggtggac 1500
cacatctacg atgcgattcg taactatgtt acccaaaaac cgtacagcaa ggataagttc 1560
aagctgtact tccagaaccc gcaattcatg ggtggctggg acaaggataa agagaccgac 1620
tatcgtgcga ccatcctgcg ttacggtagc aagtactatc tggcgattat ggataaaaag 1680
tacgcgaaat gcctgcagaa gatcgacaaa gacgatgtta acggtaacta cgaaaagatc 1740
aactacaagc tgctgccggg cccgaacaag atgctgccga aagtgttctt tagcaaaaag 1800
tggatggcgt actataaccc gagcgaggac atccaaaaga tctacaagaa cggtaccttc 1860
aaaaagggcg atatgtttaa cctgaacgac tgccacaagc tgatcgactt ctttaaagat 1920
agcattagcc gttatccgaa gtggagcaac gcgtacgatt tcaactttag cgagaccgaa 1980
aagtataaag acatcgcggg tttttaccgt gaggttgagg aacagggcta taaagtgagc 2040
ttcgaaagcg cgagcaagaa agaggtggat aaactggtgg aggaaggtaa actgtacatg 2100
ttccaaatct acaacaagga cttcagcgat aagagccacg gcaccccgaa cctgcacacc 2160
atgtacttca agctgctgtt tgacgaaaac aaccatggtc agatccgtct gagcggtggc 2220
gcggagctgt tcatgcgtcg tgcgagcctg aagaaagagg agctggttgt gcacccggcg 2280
aacagcccga ttgcgaacaa aaacccggat aacccgaaaa agaccaccac cctgagctac 2340
gacgtgtata aggataaacg ttttagcgaa gaccaatacg agctgcacat tccgatcgcg 2400
attaacaagt gcccgaaaaa catcttcaag attaacaccg aagttcgtgt gctgctgaaa 2460
cacgacgata acccgtatgt tatcggtatt gaccgtggcg agcgtaacct gctgtacatc 2520
gtggttgtgg acggtaaagg caacattgtg gaacagtata gcctgaacga gattatcaac 2580
aactttaacg gtatccgtat taagaccgat taccacagcc tgctggacaa aaaggagaag 2640
gaacgtttcg aggcgcgtca gaactggacc agcatcgaaa acattaagga gctgaaagcg 2700
ggctatatca gccaagttgt gcacaagatt tgcgaactgg ttgagaaata cgatgcggtg 2760
atcgcgctgg aggacctgaa cagcggtttt aagaacagcc gtgttaaggt ggaaaagcag 2820
gtttaccaaa agttcgagaa gatgctgatc gataagctga actacatggt ggacaaaaag 2880
agcaacccgt gcgcgaccgg tggcgcgctg aaaggttatc agattaccaa caagttcgaa 2940
agctttaaaa gcatgagcac ccaaaacggc ttcatctttt acattccggc gtggctgacc 3000
agcaaaatcg atccgagcac cggttttgtt aacctgctga agaccaaata taccagcatt 3060
gcggatagca aaaagttcat cagcagcttt gaccgtatta tgtacgtgcc ggaggaagac 3120
ctgttcgagt ttgcgctgga ctataagaac ttcagccgta ccgacgcgga ctacatcaaa 3180
aagtggaaac tgtacagcta tggtaaccgt atccgtattt tccgtaaccc gaaaaagaac 3240
aacgtttttg actgggagga agtgtgcctg accagcgcgt ataaggaact gttcaacaaa 3300
tacggtatca actatcagca aggcgatatt cgtgcgctgc tgtgcgagca gagcgacaag 3360
gcgttctaca gcagctttat ggcgctgatg agcctgatgc tgcaaatgcg taacagcatc 3420
accggtcgta ccgatgttga ttttctgatc agcccggtga aaaacagcga cggcattttc 3480
tacgatagcc gtaactatga agcgcaggag aacgcgattc tgccgaagaa cgcggacgcg 3540
aacggtgcgt ataacatcgc gcgtaaagtt ctgtgggcga ttggccagtt caaaaaggcg 3600
gaggacgaaa agctggataa ggtgaaaatc gcgattagca acaaagaatg gctggagtac 3660
gcgcaaacca gcgttaagca cgagaacctg tacttccaat cccaccacca ccaccaccac 3720
caccaccacc accaccacca ctga 3744
<210>15
<211>33
<212>DNA
<213>Artificial Sequence
<220>
<223>ofr1a-C-RT-RPA-F
<400>15
actggtactggtcaggcaataacagttacaccg 33
<210>16
<211>32
<212>DNA
<213>Artificial Sequence
<220>
<223>ofr1a-C-RT-RPA-R
<400>16
ttgtgcatcagctgactgaagcatgggttcgc 32
<210>17
<211>34
<212>DNA
<213>Artificial Sequence
<220>
<223>orf1b-N-RT-RPA-F
<400>17
cacaccgtttctatagattagctaatgagtgtgc 34
<210>18
<211>33
<212>DNA
<213>Artificial Sequence
<220>
<223>orf1b-N-RT-RPA-R
<400>18
tgcgtaaaactcattcacaaagtctgtgtcaac 33
<210>19
<211>32
<212>DNA
<213>Artificial Sequence
<220>
<223>E-RT-RPA-F
<400>19
tgtactcattcgtttcggaagagacaggtacg 32
<210>20
<211>35
<212>DNA
<213>Artificial Sequence
<220>
<223>E-RT-RPA-R
<400>20
tagaccagaagatcaggaactctagaagaattcag 35
<210>21
<211>33
<212>DNA
<213>Artificial Sequence
<220>
<223>N-RT-RPA-F
<400>21
ctaacaatgctgcaatcgtgctacaacttcct 33
<210>22
<211>33
<212>DNA
<213>Artificial Sequence
<220>
<223>N-RT-RPA-R
<400>22
ttcttagtgacagtttggccttgttgttgttgg 33
Claims (6)
1. A Cpf1 kit for rapidly detecting new coronavirus SARS-CoV-2 nucleic acid is characterized by comprising a Cpf1 fluorescence detection system suitable for rapidly detecting new coronavirus SARS-CoV-2; the Cpf1 fluorescence detection system comprises: specific crRNA, Cpf1 protein and ssDNA reporter system for the detection segments of the orf1a, orf1b, N and E genes of the novel coronavirus SARS-CoV-2;
the specific crRNA is any one or more of orf1a-crRNA1 to orf1a-crRNA2 for orf1a gene, orf1b-crRNA1 to orf1b-crRNA3 for orf1b gene, N-crRNA1 to N-crRNA2 for N gene and E-crRNA1 to E-crRNA2 for E gene, and the sequence of the specific crRNA is SEQ NO.1 to SEQ NO. 9;
the ssDNA report system comprises ssDNA FQreporters used for fluorescence detection of a microplate reader or direct visual interpretation under a fluorescent lamp, the ssDNA FQ reporters are ssDNA labeled by 6-carboxyfluorescein and a fluorescence quencher, and the labeled products are as follows: the gene is/56 FAM/TTTATTT/3BHQ1/, named ssDNA FQ reporter/56 FAM/TTTATTT/3BHQ 1/.
2. The Cpf1 kit for rapid detection of neocoronavirus SARS-CoV-2 nucleic acid of claim 1, wherein the specific crRNA is: orf1a-crRNA1 and orf1a-crRNA2 mixed in equal proportion are named orf1 a-crRNAmix; or orf1b-crRNA1, orf1b-crRNA2 and orf1b-crRNA3 which are mixed in equal proportion and are named orf1 b-crRNAmix; or N-crRNA1 and N-crRNA2 which are mixed in equal proportion and are named as N-crRNAmix; or E-crRNA1 and E-crRNA2 which are mixed in equal proportion and are named as E-crRNAmix.
3. The method for preparing Cpf1 kit for rapid detection of neocoronavirus SARS-CoV-2 nucleic acid according to claim 1 or 2, wherein the method for preparing the specific crRNA comprises: aiming at SARS-CoV-2 virus nucleic acid orf1a, orf1b, N and E genes with the sequences from SEQ NO.10 to SEQ NO.13, searching a targeting sequence containing a cpf1 recognition sequence TTTN, and designing crRNA with the length of 23 bp; after the design is finished, preparing crRNA; the preparation method of the Cpf1 protein comprises the following steps: prokaryotic codon optimization is carried out on cpf1 protein nucleic acid sequence to obtain a sequence SEQ NO.14, a pET28a expression vector is constructed, low-temperature induction soluble protein expression is carried out, and target protein is obtained through affinity purification and molecular sieve purification; the preparation method of the Cpf1 protein comprises the following steps: prokaryotic codon optimization is carried out on cpf1 protein nucleic acid sequence to obtain sequence SEQ NO.14, pET28a expression vector is constructed, low-temperature induction soluble protein expression is carried out, and target protein is obtained through affinity purification and molecular sieve purification.
4. The method for preparing the Cpf1 kit for rapidly detecting the SARS-CoV-2 nucleic acid of the neocoronavirus as claimed in claim 3, wherein the preparation of the crRNA comprises constructing a vector pUC57-T7-crRNA, and obtaining the crRNA of interest by in vitro transcription; or directly synthesizing RNA corresponding to the crRNA sequence.
5. A method for rapidly detecting the nucleic acid of the novel coronavirus SARS-CoV-2, which is characterized in that the Cpf1 kit for rapidly detecting the nucleic acid of the novel coronavirus SARS-CoV-2 according to claim 1 or 2 is adopted.
6. The method for rapidly detecting the nucleic acid of the novel coronavirus SARS-CoV-2 according to claim 5, wherein the method for rapidly detecting the nucleic acid of the novel coronavirus comprises the following steps:
step a: releasing nucleic acid in a sample to be detected by using a nucleic acid quick release reagent;
step b: amplifying nucleic acid in a sample to be detected by using a reverse transcription isothermal amplification primer: b, adding the products obtained in the step a into an RT-RPA isothermal amplification system by using specific primers SEQ NO.15 to SEQ NO.22 of SARS-CoV-2 virus nucleic acid orf1a, orf1b, N and E gene fragments, and reacting for 25min at 37 ℃ to obtain specific products;
step c: detection of SARS-CoV-2 nucleic acid using the Cpf1 detection System: adding the product obtained in the step b into a Cpf1 detection system, and reacting for 25min at 37 ℃;
step d: the result of SARS-CoV-2 virus nucleic acid is read by naked eye under enzyme labeling instrument or fluorescent lamp.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010091557.6A CN111187856B (en) | 2020-02-13 | 2020-02-13 | Cpf1 kit for rapid detection of new coronavirus nucleic acid and preparation method and application thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010091557.6A CN111187856B (en) | 2020-02-13 | 2020-02-13 | Cpf1 kit for rapid detection of new coronavirus nucleic acid and preparation method and application thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
CN111187856A true CN111187856A (en) | 2020-05-22 |
CN111187856B CN111187856B (en) | 2020-11-13 |
Family
ID=70704334
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010091557.6A Active CN111187856B (en) | 2020-02-13 | 2020-02-13 | Cpf1 kit for rapid detection of new coronavirus nucleic acid and preparation method and application thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN111187856B (en) |
Cited By (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111394522A (en) * | 2020-06-03 | 2020-07-10 | 圣湘生物科技股份有限公司 | Composition, kit, method and use for detecting SARS-CoV-2 |
CN111500792A (en) * | 2020-06-11 | 2020-08-07 | 亚能生物技术(深圳)有限公司 | Novel coronavirus detection kit |
CN111534643A (en) * | 2020-07-10 | 2020-08-14 | 上海科技大学 | Kit for detecting nucleic acid of respiratory tract pathogen, detection method and application |
CN111549182A (en) * | 2020-05-26 | 2020-08-18 | 广州再生医学与健康广东省实验室 | Probe and kit for detecting SARS-CoV-2 |
CN111593145A (en) * | 2020-06-11 | 2020-08-28 | 亚能生物技术(深圳)有限公司 | CRISPR/Cas12 one-step nucleic acid detection method and novel coronavirus detection kit |
CN111676324A (en) * | 2020-07-03 | 2020-09-18 | 韩山师范学院 | Method for detecting new coronavirus based on RAA-LFD |
CN111808991A (en) * | 2020-07-09 | 2020-10-23 | 深圳市第二人民医院(深圳市转化医学研究院) | Gene detection method and system based on RT-RPA system and CRISPR/Cas system and application thereof |
CN112980844A (en) * | 2021-03-19 | 2021-06-18 | 华南师范大学 | Detection kit for SARS-CoV-2 with transcription activity and use method |
CN113025749A (en) * | 2021-02-01 | 2021-06-25 | 天津科技大学 | Visual virus detection method based on CRISPR-Cas12a system and application |
CN113122648A (en) * | 2021-03-30 | 2021-07-16 | 中国检验检疫科学研究院 | Rapid detection kit for pathogenic bacteria of rape black leg disease and use method thereof |
CN113215164A (en) * | 2021-06-21 | 2021-08-06 | 南方医科大学 | Method for detecting novel coronavirus variant and subtype |
CN113249499A (en) * | 2021-02-26 | 2021-08-13 | 王伟佳 | Salmonella typhi detection kit, and preparation method and application thereof |
CN113403424A (en) * | 2021-05-28 | 2021-09-17 | 华南理工大学 | Method and kit for rapidly detecting new coronavirus and mutant strain based on CRISPR/Cas12a technology |
CN113512548A (en) * | 2021-07-16 | 2021-10-19 | 江门市妇幼保健院 | Novel coronavirus detection kit based on CRISPR-Cas12a system and application thereof |
RU2761170C1 (en) * | 2020-12-04 | 2021-12-06 | Федеральное государственное бюджетное учреждение науки Институт химической биологии и фундаментальной медицины Сибирского отделения Российской академии наук (ИХБФМ СО РАН) | METHOD FOR IDENTIDYING THE RNA OF THE SARS-CoV2 VIRUS USING MULTIPLEX ISOTHERMAL LOOP AMPLIFICATION WITH REVERSE TRANSCRIPTION |
WO2021250617A1 (en) * | 2020-06-10 | 2021-12-16 | King Abdullah University Of Science And Technology | A rapid multiplex rpa based nanopore sequencing method for real-time detection and sequencing of multiple viral pathogens |
CN114072422A (en) * | 2020-06-04 | 2022-02-18 | 山东博安生物技术股份有限公司 | Neutralizing antibody of SARS-CoV-2 virus and its application |
CN114080455A (en) * | 2020-06-15 | 2022-02-22 | 国立大学法人长崎大学 | Primer set for SARS-CoV-2 detection, method for detecting SARS-CoV-2, SARS-CoV-2 detection reagent, and detection kit |
WO2022174050A1 (en) * | 2021-02-12 | 2022-08-18 | The Board Of Regents For Oklahomaagricultural And Mechanical Colleges | Compositions and kits for rapid detection of sars-cov-2 and methods of production and use thereof |
CN115094060A (en) * | 2022-06-23 | 2022-09-23 | 湖南农业大学 | Kit and method for visual detection of PCV2 nucleic acid based on LAMP-CRISPR/Cas12a |
US11453907B2 (en) * | 2020-03-23 | 2022-09-27 | The Broad Institute, Inc. | Crispr effector system based coronavirus diagnostics |
CN116479175A (en) * | 2023-03-13 | 2023-07-25 | 广州国家实验室 | Detection system, kit and method for detecting human parainfluenza virus nucleic acid |
CN116622915A (en) * | 2023-06-02 | 2023-08-22 | 江苏为真生物医药技术股份有限公司 | 2019-nCOV one-step detection system based on RPA-CRISPR and application thereof |
WO2023202303A1 (en) * | 2022-04-21 | 2023-10-26 | 之江实验室 | Micro-rna detection method and kit |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20190241954A1 (en) * | 2017-11-22 | 2019-08-08 | The Regents Of The University Of California | Type v crispr/cas effector proteins for cleaving ssdnas and detecting target dnas |
CN110551846A (en) * | 2019-08-19 | 2019-12-10 | 上海科技大学 | cpf1 kit for quickly detecting African swine fever virus nucleic acid and detection method thereof |
CN110567951A (en) * | 2019-09-19 | 2019-12-13 | 河南农业大学 | Apple stem groove virus visual detection system based on CRISPR-Cas12a technology and detection method thereof |
-
2020
- 2020-02-13 CN CN202010091557.6A patent/CN111187856B/en active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20190241954A1 (en) * | 2017-11-22 | 2019-08-08 | The Regents Of The University Of California | Type v crispr/cas effector proteins for cleaving ssdnas and detecting target dnas |
CN110551846A (en) * | 2019-08-19 | 2019-12-10 | 上海科技大学 | cpf1 kit for quickly detecting African swine fever virus nucleic acid and detection method thereof |
CN110567951A (en) * | 2019-09-19 | 2019-12-13 | 河南农业大学 | Apple stem groove virus visual detection system based on CRISPR-Cas12a technology and detection method thereof |
Non-Patent Citations (2)
Title |
---|
JANICE S. CHEN等: "CRISPR-Cas12a target binding unleashes indiscriminate single-stranded DNase activity", 《SCIENCE》 * |
WORLD HEALTH ORGANIZATION: "Molecular assays to diagnose COVID-19", 《MOLECULAR ASSAYS TO DIAGNOSE COVID-19: SUMMARY TABLE OF AVAILABLE PROTOCOLS》 * |
Cited By (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11453907B2 (en) * | 2020-03-23 | 2022-09-27 | The Broad Institute, Inc. | Crispr effector system based coronavirus diagnostics |
US11639523B2 (en) | 2020-03-23 | 2023-05-02 | The Broad Institute, Inc. | Type V CRISPR-Cas systems and use thereof |
US11851702B2 (en) | 2020-03-23 | 2023-12-26 | The Broad Institute, Inc. | Rapid diagnostics |
CN111549182B (en) * | 2020-05-26 | 2023-09-29 | 生物岛实验室 | Probe and kit for detecting SARS-CoV-2 |
CN111549182A (en) * | 2020-05-26 | 2020-08-18 | 广州再生医学与健康广东省实验室 | Probe and kit for detecting SARS-CoV-2 |
CN111394522A (en) * | 2020-06-03 | 2020-07-10 | 圣湘生物科技股份有限公司 | Composition, kit, method and use for detecting SARS-CoV-2 |
CN114072422A (en) * | 2020-06-04 | 2022-02-18 | 山东博安生物技术股份有限公司 | Neutralizing antibody of SARS-CoV-2 virus and its application |
WO2021250617A1 (en) * | 2020-06-10 | 2021-12-16 | King Abdullah University Of Science And Technology | A rapid multiplex rpa based nanopore sequencing method for real-time detection and sequencing of multiple viral pathogens |
CN111593145A (en) * | 2020-06-11 | 2020-08-28 | 亚能生物技术(深圳)有限公司 | CRISPR/Cas12 one-step nucleic acid detection method and novel coronavirus detection kit |
CN111500792A (en) * | 2020-06-11 | 2020-08-07 | 亚能生物技术(深圳)有限公司 | Novel coronavirus detection kit |
CN114080455A (en) * | 2020-06-15 | 2022-02-22 | 国立大学法人长崎大学 | Primer set for SARS-CoV-2 detection, method for detecting SARS-CoV-2, SARS-CoV-2 detection reagent, and detection kit |
CN111676324A (en) * | 2020-07-03 | 2020-09-18 | 韩山师范学院 | Method for detecting new coronavirus based on RAA-LFD |
CN111808991A (en) * | 2020-07-09 | 2020-10-23 | 深圳市第二人民医院(深圳市转化医学研究院) | Gene detection method and system based on RT-RPA system and CRISPR/Cas system and application thereof |
CN111534643A (en) * | 2020-07-10 | 2020-08-14 | 上海科技大学 | Kit for detecting nucleic acid of respiratory tract pathogen, detection method and application |
RU2761170C1 (en) * | 2020-12-04 | 2021-12-06 | Федеральное государственное бюджетное учреждение науки Институт химической биологии и фундаментальной медицины Сибирского отделения Российской академии наук (ИХБФМ СО РАН) | METHOD FOR IDENTIDYING THE RNA OF THE SARS-CoV2 VIRUS USING MULTIPLEX ISOTHERMAL LOOP AMPLIFICATION WITH REVERSE TRANSCRIPTION |
CN113025749A (en) * | 2021-02-01 | 2021-06-25 | 天津科技大学 | Visual virus detection method based on CRISPR-Cas12a system and application |
WO2022174050A1 (en) * | 2021-02-12 | 2022-08-18 | The Board Of Regents For Oklahomaagricultural And Mechanical Colleges | Compositions and kits for rapid detection of sars-cov-2 and methods of production and use thereof |
WO2022179494A1 (en) * | 2021-02-26 | 2022-09-01 | 王伟佳 | Salmonella typhi detection kit, preparation method therefor and application thereof |
CN113249499A (en) * | 2021-02-26 | 2021-08-13 | 王伟佳 | Salmonella typhi detection kit, and preparation method and application thereof |
CN113249499B (en) * | 2021-02-26 | 2022-04-05 | 王伟佳 | Salmonella typhi detection kit, and preparation method and application thereof |
CN112980844A (en) * | 2021-03-19 | 2021-06-18 | 华南师范大学 | Detection kit for SARS-CoV-2 with transcription activity and use method |
CN113122648A (en) * | 2021-03-30 | 2021-07-16 | 中国检验检疫科学研究院 | Rapid detection kit for pathogenic bacteria of rape black leg disease and use method thereof |
CN113403424A (en) * | 2021-05-28 | 2021-09-17 | 华南理工大学 | Method and kit for rapidly detecting new coronavirus and mutant strain based on CRISPR/Cas12a technology |
CN113403424B (en) * | 2021-05-28 | 2024-01-09 | 华南理工大学 | Method and kit for rapidly detecting novel coronaviruses and mutant strains based on CRISPR/Cas12a technology |
CN113215164A (en) * | 2021-06-21 | 2021-08-06 | 南方医科大学 | Method for detecting novel coronavirus variant and subtype |
CN113215164B (en) * | 2021-06-21 | 2022-06-07 | 南方医科大学 | Method for detecting novel coronavirus variant and subtype |
CN113512548A (en) * | 2021-07-16 | 2021-10-19 | 江门市妇幼保健院 | Novel coronavirus detection kit based on CRISPR-Cas12a system and application thereof |
WO2023202303A1 (en) * | 2022-04-21 | 2023-10-26 | 之江实验室 | Micro-rna detection method and kit |
CN115094060A (en) * | 2022-06-23 | 2022-09-23 | 湖南农业大学 | Kit and method for visual detection of PCV2 nucleic acid based on LAMP-CRISPR/Cas12a |
CN116479175A (en) * | 2023-03-13 | 2023-07-25 | 广州国家实验室 | Detection system, kit and method for detecting human parainfluenza virus nucleic acid |
CN116622915A (en) * | 2023-06-02 | 2023-08-22 | 江苏为真生物医药技术股份有限公司 | 2019-nCOV one-step detection system based on RPA-CRISPR and application thereof |
Also Published As
Publication number | Publication date |
---|---|
CN111187856B (en) | 2020-11-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN111187856B (en) | Cpf1 kit for rapid detection of new coronavirus nucleic acid and preparation method and application thereof | |
CN110551846B (en) | Cpf1 kit for quickly detecting African swine fever virus nucleic acid and detection method thereof | |
CN111778357B (en) | CRISPR/Cas12 a-based respiratory syncytial virus nucleic acid rapid detection kit and detection method thereof | |
JP7374377B2 (en) | Test kit for Salmonella typhi, its manufacturing method, and its uses | |
CN111521781B (en) | Detection kit for SARS-CoV-2 nucleic acid of new coronary pneumonia virus and detection method thereof | |
CN111534635A (en) | Integrated molecular diagnosis system and application thereof in tracing beta coronavirus animal source | |
CN112725487A (en) | Nucleic acid rapid detection kit for streptomycin drug-resistant mycobacterium tuberculosis and detection method thereof | |
CN113046475A (en) | Primer composition and kit for rapidly detecting mutant type novel coronavirus | |
CN112739833A (en) | Primer pair, probe and kit for detecting SARS-CoV-2 by utilizing nested RPA technology and application thereof | |
CN114015792B (en) | Fluorescent kit for detecting Brucella and detection method | |
CN113637806A (en) | Kit for foot-and-mouth disease virus detection and detection method thereof | |
CN117210584A (en) | Kit for multiplex detection of streptococcus pneumoniae, haemophilus influenzae, chlamydia pneumoniae and mycoplasma pneumoniae nucleic acids | |
CN114134218B (en) | Fluorescent detection method based on CRISPR-Cas12a | |
CN116042878A (en) | Kit and detection method for detecting and distinguishing Brucella | |
CN116479093A (en) | Rhinoceros nucleic acid rapid detection method and detection kit based on CRISPR fluorescence method | |
CN106521038B (en) | A kind of real-time fluorescence quantitative PCR detection methods of highly sensitive BHV 2 and kit | |
CN112852980B (en) | Detection method for detecting nucleic acid of Atlantic salmon based on CRISPR fluorescence method and detection kit thereof | |
CN112980844A (en) | Detection kit for SARS-CoV-2 with transcription activity and use method | |
CN113549709A (en) | Primer pair, probe and kit for detecting SARS-CoV-2 by utilizing nested RPA technology and application thereof | |
CN116004870B (en) | Kit and detection method for detecting and identifying Brucella | |
Zhang et al. | Based on CRISPR-Cas13a system, to establish a rapid visual detection method for avian influenza viruses | |
CN118086575B (en) | Method for visually detecting phytophthora cowpea based on RPA-CRISPR/Cas12a and application | |
CN116515840B (en) | Kit and detection method for detecting bovine viral diarrhea virus type 3 | |
CN118056914A (en) | NDM-type carbapenemase gene detection kit based on PCR/RAA-CRISPR-Cas13a | |
CN116218854A (en) | Kit for detecting silkworm corpuscles and detection method thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |